Pfizer

•

Κανάλι • 7 εκπομπές

Βιολογικές επιστήμες

Βιολογικές επιστήμες

21/11/2023
Βιολογικές επιστήμες

Βιολογικές επιστήμες

15/12/2025
Βιολογικές επιστήμες

Βιολογικές επιστήμες

Εβδομαδιαία
Ιατρική

Ιατρική

Εβδομαδιαία
Επιστημονική φαντασία

Επιστημονική φαντασία

Σειρά
Βιολογικές επιστήμες

Βιολογικές επιστήμες

Μηνιαία
Ιατρική

Ιατρική

04/12/2024

30/06/2020

#COVID19: Teamwork Makes the Dream Work

In the last episode of The Antigen’s #COVID19 mini-series, we examine the teamwork & collaboration across communities in the fight against coronavirus. How are companies working together to develop potential vaccines for COVID-19? How has the global health community at large been helpful in responding to the pandemic? Host Lindsey Dietschi speaks with two guests — Elsie Soto, Vice President of Emerging Markets for Pfizer’s Global Supply & Dr. Frank Mahoney, Senior Immunization Officer at the International Federation of Red Cross and Red Crescent Societies (IFRC). For the latest updates, visit pfizer.com/coronavirus.
10/12/2019

Vaccines 101

Vaccines have saved millions of lives, but they’ve also become victims of their own success. They’ve done such a good job that we’ve forgotten what serious infections like polio and diphtheria look like. On the first episode of The Antigen, host Yasmeen Agosti takes us through vaccine basics with the help of experts Dr. Kathryn Edwards, Dr. Peter Hotez, Martha Rebour, LJ Tan, and Serese Marotta, who explain why vaccines are more relevant now than ever.
24/12/2019

The History of Vaccines

From the first inoculations in China and the Middle East, to Edward Jenner and his smallpox immunization, all the way to the inception of vaccines we still use today — this episode of The Antigen is all about the history of vaccines. New voices like Emilio Emini, Stanley Plotkin, Sarah Long, and Todd Wolynn join familiar guests from the first episode to paint a historical picture of this scientific innovation.
26 Φεβ

Bringing Cancer Into Focus: Biomarkers & Precision Medicine

What if the key to treating cancer was hiding in plain sight – written into its DNA? In this episode of Science Will Win, host Dr. Raven Baxter explores one of the most exciting breakthroughs in cancer care today: the discovery of biomarkers. These tiny molecular signals are helping doctors understand what’s really driving an individual person’s cancer – and opening the door to treatments that can dramatically change patient outcomes. You’ll hear powerful stories from people whose cancers were traced back to a specific biomarker, alongside experts who break down what biomarker testing is, how it works, and why it’s transforming the way we think about cancer treatment. Biomarkers are showing us that when we understand cancer at its molecular level, a disease that once felt like an unsolvable mystery starts to come into focus. Featured guests: – Dr. Ross Camidge, Director of Thoracic Oncology, University of Colorado – Kelly Huffman, Lung Cancer Patient and Retail Account Manager, Pfizer – Karin Tollefson, Chief Oncology Medical Officer, Pfizer Dive into the episode here: 00:00 – An oncologist’s diagnosis introduces the world of biomarker 03:10 – Defining biomarkers and its history 06:24 – Discovery of the first lung cancer biomarker 08:39 – The start Kelly’s lung cancer journey 16:00 – Biomarkers: how do you test for them? 19:11– Discovery of ALK biomarker shift’s Kelly’s story 22:34 – Landscape of targeted therapy and lung cancer today 25:24 – Moving forward with targeted treatments and conclusion Check out our YouTube channel (@Pfizer) to watch the full interview with Raven & Kelly Huffman on her lung cancer journey. Season 6 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter. It’s produced by Acast Creative Studios. Hosts in this podcast series were compensated for their time. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
2 Απρ

The Pace of Science: AI in Cancer Care

Cancer research is moving faster than ever—but too many patients never feel the impact of that progress. Artificial Intelligence (AI) is emerging as one tool that could help change that. In the Season 6 finale of Science Will Win, Dr. Raven Baxter follows the human journey behind AI in oncology—from the moment of diagnosis to the real‑world barriers that determine access to care. Along the way, we explore how thoughtfully designed artificial intelligence is reshaping trial design, enrollment, eligibility, and access—helping patients regain agency and bridging the gap between scientific breakthroughs and real‑world cancer care. As the season concludes, one thing is clear: progress matters most when it reaches the people who need it. Featured guests: – Dr. Lionel Kankeu Fonkoua, Medical Oncologist and Translational Researcher, Mayo Clinic – Jeff Legos, Chief Oncology Officer, Pfizer – Dr. Ravi Parikh, Medical Oncologist; Director, Human‑Algorithm Collaboration Lab – Maya R. Said, Founder and CEO, Outcomes4Me Dive into the episode here: 00:00 – Past episodes introduce us to an emerging tech advancement 04:16 – What is a clinical trial? 07:35 – AI accelerating the pace of oncology 12:42 – Clinical trials and AI: How can it help? 16:17 – A gap between innovation and patient access 19:16 – Maya's story 23:47 – Clinical trials for AI tools 27:54 – Conclusion: building pathways alongside scientific innovation Check out our YouTube channel (@Pfizer) to watch full interviews between Raven & some of the patients featured. Season 6 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter. It’s produced by Acast Creative Studios. Hosts in this podcast series were compensated for their time. *The content in this episode is for informational purposes only and does not provide medical advice. Pfizer does not endorse or sponsor third‑party tools referenced. Patients should not use the tools described as a replacement for discussions with a healthcare provider. Patients should consult their healthcare provider regarding medical decisions. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
11/11/2025

Part 3 — Getting Attached to Molecular Glues

Protein-protein interactions facilitate numerous bodily processes – everything from the basics of how our muscles contract to the more complex ways cancer can spread through the body. So, what if there was a way to alter some of these interactions? Or even create new ones? In this episode, we’re diving into the fascinating field of molecular glues, a revolutionary modality on the precipice of changing the treatment landscape for certain cancers and potentially other diseases and conditions. Featured Guests: – Joyann Donaldson, Principal Scientist, Synthesis Group Lead, Pfizer – Jennifer LaFontaine, Head of Oncology Medicinal Chemistry, Pfizer – Neal Sach, Research Fellow, Pfizer – Jillian Spangler, Associate Research Fellow, Pfizer Dive into the episode here: 0:50 - A metaphor to explain molecular glues 2:36 - How do molecular glues work in the body? 5:57 - A new frontier for cancer treatment 13:05 - The history behind molecular glues 16:59 - How do scientists design molecular glues? 19:05 - A visit to Pfizer’s La Jolla labs 32:42 - How can molecular glues change the patient experience? 36:42 - Molecular glues beyond cancer treatment Season 5 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter and Dr. Ronald Gamble. It’s produced by Acast Creative Studios. Check out our social media platforms to take a deeper look into the labs and stories we discuss during the episodes: Instagram (@pfizerinc), TikTok (@pfizer) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
07/01/2020

Global Perspectives, Barriers, and Solutions

With preventable disease rates dropping around the world, vaccination efforts are largely a success. What are the barriers that still prevent vaccines from reaching the people who need them? This episode of The Antigen is going global. Host Yasmeen Agosti talks with experts about worldwide efforts to make vaccines more accessible, from organizations like The Bill and Melinda Gates Foundation, GAVI, Shot@Life, Save the Children, and The Wellcome Trust. Episode references: Wellcome Global Monitor 2018
04/03/2025

Part 4 – New Frontiers in AI & Drug Discovery

So far in this season, we’ve explored how innovations throughout history have brought us to where we are now. We talked about how drug discovery changed from a serendipity-based to data-based endeavor. Then, we explored the powerful hardware and smart software required to accommodate big data. Now, the door to the future of AI in drug discovery is open. In our final episode, we’re looking toward the future, to understand where today’s advancements could potentially take us. Featured Guests: –Charlotte Allerton, Head of Preclinical and Translational Sciences at Pfizer –Daniel Ziemek, Vice President of Integrative Biology and Systems Immunology at Pfizer –Enoch Huang, Head of Machine Learning and Computational Sciences at Pfizer –Dr. Raza Ali, group leader at the University of Cambridge Cancer Research UK Institute, pathologist Season 4 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
18/04/2024 · Επιπρόσθετο περιεχόμενο

Live from SXSW - Moonshot Culture: Innovating to Outdo Yesterday

Throughout history, humans have coalesced around moonshot culture to achieve audacious goals—from eradicating smallpox, to sequencing the human genome, to landing a spacecraft on Mars. These feats of human ingenuity didn’t happen in a vacuum, they were born from intentional innovation, a “coalition of the willing,” and a vision to outdo yesterday. This fireside chat with Drew Panayiotou, Former CMO of Pfizer and Devon Still, ex-NFL player and founder of Still Strong Foundation, explores innovations in cancer, their personal experiences with family members needing healthcare treatment, and what it will take to achieve Pfizer's next big moonshot to outdo cancer and achieve its vision, a world where people with cancer live better and longer lives. This episode was recorded live in Austin, TX on Monday March 11 as part of Pfizer’s takeover of the South by Southwest podcasting lounge. The Let's Outdo Cancer Campaign aims to focus on advances in fighting against cancer. To learn more, visit letsoutdocancer.com. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
12 Μαρ

Living Longer with Cancer: Rethinking Survivorship

What comes after a cancer diagnosis and treatment? In this episode of Science Will Win, host Dr. Raven Baxter explores one of the most important, and often overlooked, chapters for cancer patients: survivorship. As five-year survival rates climb to 70%, more people than ever are living with and beyond cancer. But longer survival brings its own complex challenges, and our care systems are still catching up. You'll hear from experts and advocates working at the intersection of medicine, policy, and community. We’ll discuss what it really takes to support people through this transition — when the clinical benchmarks have passed and it’s time to go back to “normal life”. From patient care plans and workplace disclosure to mental health, this episode makes one thing clear: survivorship demands dignity, support, and a whole new kind of care. Featured guests: – Tina Deignan, Commercial President, Pfizer Oncology – Shelley Fuld Nasso, CEO, Cancer Nation – Rebecca Nellis, Executive Director, Cancer and Careers – Bob Riter, Breast Cancer Patient & Advocate Dive into the episode here: 00:00 – The ongoing battle with cancer 03:43 – Rethinking survivorship 05:32 – The five-year survival myth 07:00 – The history of the term "survivor" 09:36 – Bob’s journey with breast cancer 11:38 – Lost in transition and survivorship care plans 14:25 – The intersection of cancer and work 18:49 – Rethinking how work gets done 20:00 – Disclosure and improving company culture 20:59 – The swivel technique 23:19 – Controlling your narrative 25:11 – Standardizing long-term survivorship care through policy 27:08 – Lack of access to care leads to disparities in survival rates 29:48 – Bob's second journey with cancer 32:21 – Takeaways and peek into our final episode Check out our YouTube channel (@Pfizer) to watch the full interview with Raven & Bob Riter on his cancer journey. Season 6 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter. It’s produced by Acast Creative Studios. Hosts in this podcast series were compensated for their time. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Go behind the breakthroughs and explore the stories of the work we do at Pfizer around the globe, in conversations with the scientists and leaders who make it happen. Listen to recent episodes and follow along.

Ιστότοπος

Pfizer

Κορυφαίες εκπομπές

Κορυφαία επεισόδια

Σχετικά με το podcast